Thomas Murphy, MD
Allergy & Immunology · Charleston, SCNPI 1144275827
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $545,044 of the $652,950 with a category attached, or 83.5%. 32 manufacturers reported payments, led by AstraZeneca at 47.3% of the total. Among allergy & immunology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,049 payments — averaging $622.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$309K
- Sanofi$88K
- Optinose US, Inc.$69K
- Regeneron Healthcare Solutions, Inc.$54K
- GSK$52K
- Genentech USA, Inc.$44K
- plus $37K from 26 others
Across 727 payments — averaging $1099.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$191K
- Regeneron$162K
- AstraZeneca$161K
- Incyte Corporation$112K
- Paratek Pharmaceuticals, Inc.$72K
- Optinose US, Inc.$53K
- plus $48K from 4 others
What the payments were for
- Consulting fees$40,2286%
- Speaking & faculty fees$545,04483%
- Travel & lodging$45,6127%
- Food & beverage$21,6163%
- Education$4520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 463 | $309,073 |
| Sanofi | 106 | $88,097 |
| Optinose US, Inc. | 99 | $68,755 |
| Regeneron Healthcare Solutions, Inc. | 93 | $53,957 |
| GSK | 69 | $52,216 |
| Genentech USA, Inc. | 63 | $43,618 |
| F. Hoffmann-la Roche AG | 13 | $12,329 |
| Amgen | 11 | $8,040 |
| Novartis | 15 | $6,259 |
| Alk-abello, Inc | 16 | $3,785 |
| Genentech, Inc. | 10 | $3,414 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $297 |
| Grifols USA, LLC | 13 | $265 |
| Pharming Healthcare, Inc. | 12 | $242 |
| Sanofi-aventis U.S. LLC | 4 | $211 |
| CSL Behring | 7 | $179 |
| Stryker | 1 | $176 |
| Pfizer | 8 | $138 |
| Kaleo, Inc. | 7 | $118 |
| Hikma Pharmaceuticals USA | 6 | $101 |
| Biocryst US Sales Co., LLC | 3 | $90 |
| Neurent Medical Limited | 1 | $90 |
| Ionis Pharmaceuticals, Inc. | 3 | $72 |
| Aerin Medical Inc. | 1 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Blueprint Medicines Corporation | 2 | $42 |
| Intersect ENT, Inc. | 1 | $42 |
| Phadia US Inc. | 2 | $37 |
| Merck | 2 | $35 |
| Incyte Corporation | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$652,950 in reported general payments places this provider in the 95th percentile of 46 allergy & immunology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 37 | $165,423 |
| Dupixent SyringeDupilumab | 11 | $74,071 |
| XolairOmalizumab | 14 | $48,474 |
| Spiriva RespimatTiotropium Bromide | 30 | $23,661 |
| Azelastine Hcl | 519 | $14,262 |
| Epinephrine | 51 | $8,962 |
| XhanceFluticasone Propionate | 12 | $8,794 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,233 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $6,761 |
| Fluticasone Propionate | 325 | $5,125 |
| DuleraMometasone/Formoterol | 13 | $4,484 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $3,192 |
| Ipratropium Bromide | 99 | $3,044 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $2,391 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $3,414 | $48,47414 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $52,216 | $10,60123 claims |
| Hikma Pharmaceuticals USAEpinephrine | $101 | $8,96251 claims |
| Optinose US, Inc.Xhance | $68,755 | $8,79412 claims |
| AstraZenecaSymbicort | $309,073 | $6,76122 claims |
| MerckDulera | $35 | $4,48413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 46 allergy & immunology providers in South Carolina.
Other allergy & immunology in Charleston
- Andrew DavidsonCharleston$14K
- Carolyn WordCharleston$10K
- Jeffrey DietrichCharleston$8K
- Lindsey SteadmanCharleston$6K
- Brian DantzlerCharleston$2K
- Thomas HarperCharleston$504
- Douglas JohnstonGreenville$329K
- Allen KaplanNorth Charleston$220K
- David AmrolColumbia$172K
- Ned RuppNorth Charleston$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.